Application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases

An antiviral drug and nucleoside technology, applied in the field of medicine, can solve problems such as increased risk of thrombosis, achieve the effects of reducing severity and frequency, inhibiting P-selectin expression, and inhibiting activation

Inactive Publication Date: 2020-08-25
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Excess thrombin generation leads to translocation of P-selectin, ultimately leading to increased risk of thrombosis
[0005] CONCLUSIONS: The antiplatelet effects of antiviral drugs may attenuate the risk of HSV-associated infarct disease development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases
  • Application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases
  • Application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] This embodiment combines Figure 1~3 Effects of famciclovir on platelet aggregation, platelet GPIIb / IIIa activation, and P-selectin expression will be described.

[0040] (1) The experimental method for studying the influence of famciclovir on the degree of platelet aggregation is as follows:

[0041] Get male C57BL / 6 mice (25-30g) and divide into random groups (N=6), respectively model control group, model group, famciclovir low-dose group (LFCV, 60mg / kg), famciclovir high-dose group (HFCV, 120mg / kg). kg), administered once a day for seven consecutive days. The model control group was given an equal volume of solvent saline in the same way. On the evening of the seventh day, the C57BL / 6 mice were fasted without water.

[0042] On the day of the experiment, mice were anesthetized by intraperitoneal injection of 3.5% pentobarbital sodium solution, blood was collected by heart puncture, and immediately mixed with 3.8% sodium citrate anticoagulant at a volume ratio of 9...

Embodiment 2

[0048] This embodiment combines Figure 4~6 The effects of famciclovir on arterial and venous thrombosis are described.

[0049] (1) The experimental method for studying the influence of famciclovir on arterial thrombosis is as follows:

[0050] Administration pre-treatment: male C57BL / 6 mice (25-30g) were randomly divided into groups (N=6), respectively model control group, model group, famciclovir low-dose group (LFCV, 60mg / kg), famciclovir high-dose group ( HFCV, 120mg / kg), administered once a day for seven consecutive days. The model control group was given an equal volume of solvent saline in the same way. On the evening of the seventh day, the C57BL / 6 mice were fasted without water.

[0051] On the eighth day, 1 hour after the last administration, C57BL / 6 mice were intraperitoneally injected with 3.5% pentobarbital sodium solution. After anesthesia, the skin was cut with surgical scissors along the midline of the mouse neck, and then the left side of the mouse was blu...

Embodiment 3

[0058] This embodiment combines Figure 7 The effect of famciclovir on cerebral infarction will be described.

[0059] The experimental method for studying the effect of famciclovir on cerebral infarction is as follows:

[0060] Administration pre-treatment: male C57BL / 6 mice (25-30g) were randomly divided into groups (N=6), respectively model control group, model group, famciclovir low-dose group (LFCV, 60mg / kg), famciclovir high-dose group ( HFCV, 120mg / kg), administered once a day for seven consecutive days. The model control group was given an equal volume of solvent saline in the same way. On the evening of the seventh day, the C57BL / 6 mice were fasted without water.

[0061] Modeling: on the eighth day, 1 hour after the last administration, C57BL / 6 mice were intraperitoneally injected with 3.5% pentobarbital sodium solution. After anesthesia, the animals were fixed on the operating table in a supine position, the neck hair was shaved, and the operation area was disin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases, relates to the technical field of medicine, and aims at providinga novel direction for researching and developing the medicine for treating the infarction diseases. According to the application of the nucleoside type antiviral medicine to preparation of the medicine for treating the infarction diseases provided by the invention, the nucleoside type antiviral medicine can reduce the serious degree and the frequency of herpes simplex virus infection, and also has the significant activity of relieving infarction complications. Studies prove that in the infarction diseases, blood platelet adhesion, activation and aggregation achieve the key regulating effects;the nucleoside type antiviral medicine, such as famciclovir can inhibit the blood platelet aggregation, inhibit the GPIIb/IIIa activation, inhibit P-selectin expression and/or inhibit arteriovenous thrombus and cerebral infarction formation; meanwhile, a blood coagulation system is not influenced; and a novel idea is provided for the research and development of medicine for treating the infarction diseases.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a nucleoside antiviral drug in the preparation of a drug for treating infarction diseases. Background technique [0002] Thrombosis plays a promoting role in the occurrence and development of infarct diseases such as unstable angina, myocardial infarction, transient ischemic attack and atherosclerosis. In the process of thrombus formation, platelet adhesion, activation and aggregation play key regulatory roles. Platelets will adhere to collagen surfaces exposed by damaged vascular endothelium, in which case platelets bind thrombosis-related substrates and are rapidly activated to locally release or produce agonists, including adenosine diphosphate (ADP), Thromboxane (TX) A and thrombin, these agonists respectively interact with the corresponding receptors on the surface of platelets, thereby promoting more platelet adhesion and aggregation. Platelet aggregat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/52A61P9/10A61P7/02
CPCA61K45/00A61K31/52A61P9/10A61P7/02
Inventor 辛光钮海
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap